SG11201809031XA - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- SG11201809031XA SG11201809031XA SG11201809031XA SG11201809031XA SG11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cognitive function
- leucine
- acetyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 0 111111101111 0 DOI 010111110101111 0 111 011111010111110110101111110111 OEN International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/182802 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: A61K 31/198 (2006.01) A61P 43/00 (2006.01) (21) International Application Number: PCT/GB2017/051090 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1606834.8 19 April 2016 (19.04.2016) GB (71) Applicant: INTRABIO LTD [GB/GB]; Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke Oxford- shire OX5 1PF (GB). (72) Inventors: FACTOR, Mallory; 27 Linton Road, Oxford Oxfordshire OX2 6UL (GB). STRUPP, Michael; Univer- sity Hospital Munich, Campus GroBhadern, Marchioninistr. 15, D-81377 Munich (DE). Agent: O'BRIEN, Simon; D Young & Co LLP, 120 Hol- born, London EC1N 2DY (GB). (74) = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (81) = _ — = = = _ PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — = _ Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) = = _ _ = = = = — = — Published: ,- 1 — ei with international search report (Art. 21(3)) © cc ei cc 1-1 N (54) Title: ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY Il AND COGNITIVE FUNCTION 0 ei (57) : The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving 0 cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809031XA true SG11201809031XA (en) | 2018-11-29 |
Family
ID=58633040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106190RA SG10202106190RA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| SG11201809031XA SG11201809031XA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106190RA SG10202106190RA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10905670B2 (en) |
| EP (1) | EP3445351A1 (en) |
| JP (2) | JP7387264B2 (en) |
| KR (4) | KR20180134398A (en) |
| CN (1) | CN109069463A (en) |
| AU (2) | AU2017252507B2 (en) |
| BR (1) | BR112018071547A2 (en) |
| CA (1) | CA3021155A1 (en) |
| IL (3) | IL310508A (en) |
| MX (2) | MX2018012739A (en) |
| RU (2) | RU2745912C2 (en) |
| SG (2) | SG10202106190RA (en) |
| WO (1) | WO2017182802A1 (en) |
| ZA (1) | ZA201806849B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7387264B2 (en) * | 2016-04-19 | 2023-11-28 | イントラバイオ リミティド | Acetyl-leucine or its pharmaceutically acceptable salts for improved mobility and cognitive function |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US20220024858A1 (en) * | 2018-12-06 | 2022-01-27 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
| EP3934637A1 (en) * | 2019-03-02 | 2022-01-12 | IntraBio Ltd | Leucine, acetyl leucine, and related analogs for treating disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (en) * | 2006-09-13 | 2010-01-15 | Pf Medicament | TREATMENT OF VERTIGS BY ACETYL-L-LEUCINE. |
| TN2010000251A1 (en) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR |
| JP7387264B2 (en) * | 2016-04-19 | 2023-11-28 | イントラバイオ リミティド | Acetyl-leucine or its pharmaceutically acceptable salts for improved mobility and cognitive function |
| MA50399A (en) * | 2017-10-18 | 2020-08-26 | Intrabio Ltd | THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS |
-
2017
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/en active Active
- 2017-04-19 MX MX2018012739A patent/MX2018012739A/en unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/en active Search and Examination
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/en not_active IP Right Cessation
- 2017-04-19 CN CN201780029480.6A patent/CN109069463A/en active Pending
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR20240018683A/en active Application Filing
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/en active IP Right Grant
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/en active
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en active Application Filing
- 2017-04-19 IL IL293266A patent/IL293266B1/en unknown
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 EP EP17719692.0A patent/EP3445351A1/en active Pending
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 RU RU2021107001A patent/RU2021107001A/en unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/en active IP Right Grant
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/en unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US20210106548A1/en active Pending
-
2021
- 2021-11-12 JP JP2021185130A patent/JP2022024058A/en active Pending
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en active Pending
-
2023
- 2023-07-10 US US18/349,221 patent/US20230346732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201806853VA (en) | Abstracted graphs from social relationship graph | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901125TA (en) | Treatment of dementia | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201809501PA (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |